

## **Cancer Immunotherapy Market & Clinical Pipeline Insight**

With more than 6 million deaths worldwide in 2013, cancer has become one of the most pressing health problems faced by almost all the economies of the world. In spite of the fact that there have been significant improvisation and advancements in surgery, radiation therapy, and chemotherapy over the years, there has hardly been any significant control of this disease by these treatments. There have been many developments in the recent past, in terms of introducing novel methods of treatment of cancer, which are likely to have a great potential. Cancer immunotherapy is one such development in the field of cancer treatment. This treatment option involves manipulating the human body's immune system in order to target the cancer.

The recent years have witnessed the emergence of cancer immunotherapy, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past 15-20 years, the researchers have increased their learning about the human body's immune system, which has led to the achievement of significant number of regulatory milestones during this period. Cancer immunotherapy has been made commercial and the market availability of the agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's immune system.

There has been some extensive research in the previous decade which has led to the development of vital novel therapies for diseases such as bladder cancer, renal cell carcinoma, colon cancer, and some leukemias. Additionally, these significant achievements in cancer immunotherapy have been popular on similar lines as improved techniques such as genetic engineering and monoclonal antibody generation. Thus, both these set of advancements have been working hand-in-hand to bring the cancer immunotherapy on the growth trajectory. The future is also likely to witness a continued close association between these two fields of advancements.

Cancer immunotherapy will continue to be overflowing with huge potential as a result of an increasing number of new discoveries and techniques. In spite of advances being made in terms of understanding of the complexities of the human immune system, as compared to the

state of immunology during Dr. Coley, there is still significant work which needs to be done. The complete detailed understanding is yet to be deciphered, which is one of the major reasons for cancer immunotherapy not being in widespread use.

**“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:**

- Cancer Immunotherapy Market Overview
- Cancer Immunotherapy Market Dynamics
- Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
- Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
- Cancer Vaccine Clinical Pipeline by Phase & Country
- Oncolytic Viruses Clinical Pipeline by Phase & Country
- Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
- Cancer Cell Therapy Clinical Trial Insight by Phase & Country
- Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline

For Report Sample Contact: [avinash@kuickresearch.com](mailto:avinash@kuickresearch.com)

## ***Table of Contents***

### ***1. Introduction to Cancer Immunotherapy (Page 6)***

### ***2. Mechanism of Cancer Immunotherapy (Page 11)***

2.1 Genetic engineering

2.2 Hybridoma Technology

2.3 Humanization of Monoclonal Antibodies

2.4 Overcoming the HAMA Response via Modern Technology

### ***3. Types of Cancer Immunotherapy (Page 14)***

3.1 Monoclonal Antibodies

3.2 Checkpoint Inhibitors

3.3 Vaccination

3.4 Non Specific Immunotherapies

**4. *Why Need for Cancer Immunotherapy (Page 23)***

**5. *Global Cancer Immunotherapy Market Overview (Page 26)***

**6. *Cancer Immunotherapy Market Dynamics (Page 33)***

6.1 Favorable Market Drivers

6.2 Key issues to be Discussed

6.3 Future of Cancer Immunotherapy

**7. *Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country (Page 41)***

7.1 Clinical Pipeline Overview

7.2 Clinical Pipeline Insight: Research till Registration

7.3 Marketed Cancer Monoclonal Antibodies

**8. *Cancer Vaccine Clinical Pipeline by Phase & Country (Page 1088)***

8.1 Clinical Pipeline Overview

8.2 Clinical Pipeline Insight: Research till Registration

8.3 Marketed Cancer Vaccines

**9. *Oncolytic Viruses Clinical Pipeline by Phase & Country (Page 1640)***

9.1 Clinical Pipeline Overview

9.2 Clinical Pipeline insight: Research till Registration

**10. *Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country (Page 1714)***

10.1 Clinical Pipeline Overview

10.2 Clinical Pipeline Insight: Research till Preregistration

10.3 Marketed Cancer Cytokines Therapy

**11. *Cancer Cell Therapy Clinical Trial Insight by Phase & Country (Page 1844)***

11.1 Clinical Pipeline Overview

11.2 Clinical Pipeline Insight: Research till Preregistration

### 11.3 Marketed Cancer Cell Therapy

## **12. Competitive Landscape: Business Overview & Product Pipeline (Page 1977)**

12.1 Advaxis

12.2 Celldex Therapeutics

12.3 Dendreon Corporation

12.4 Galena Biopharma

12.5 ImmunoCellular Therapeutics

12.6 ImmunoGen

12.7 Inovio Pharmaceuticals

12.8 Merck

12.9 NeoStem Oncology

12.10 NewLink Genetics

12.11 Northwest Biotherapeutics

12.12 Novartis

12.13 Peregrine Pharmaceuticals

12.14 Roche

12.15 Seattle Genetics

## ***List of Figures***

Figure 1-1: Introduction to Cancer Therapies

Figure 1-2: Key Events in the History of Cancer Immunotherapy

Figure 2-1: Mechanism of Cancer Immunotherapy

Figure 3-1: Type of Cancer Immunotherapy

Figure 5-1: Cancer Immunotherapy Market Category

Figure 5-2: Cancer Immunotherapy Market (US\$ Billion), 2014-2020

Figure 5-3: Cancer Immunotherapy Market by Region (%), 2014 & 2020

Figure 5-4: Regulatory Milestones for Cancer Immunotherapy

Figure 7-1: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2014

Figure 7-2: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2014

Figure 8-1: Cancer Vaccine Clinical Pipeline by Phase (%), 2014

Figure 8-2: Cancer Vaccine Clinical Pipeline by Phase (Number), 2014

Figure 9-1: Oncolytic Viruses Clinical Pipeline by Phase (%), 2014

Figure 9-2: Oncolytic Viruses Clinical Pipeline by Phase (Number), 2014

Figure 10-1: Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014

Figure 10-2: Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014

Figure 11-1: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014

Figure 11-2: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014

Figure 12-1: Advaxis Clinical Pipeline

Figure 12-2: Celldex Therapeutics Clinical Pipeline

Figure 12-3: Galena Biopharma Clinical Pipeline

Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline

Figure 12-5: ImmunoGen Clinical Pipeline

Figure 12-6: Inovio Pharmaceuticals Clinical Pipeline

Figure 12-7: NewLink Genetics Corporation Clinical Pipeline

Figure 12-8: Northwest Biotherapeutics Clinical Pipeline

Figure 12-9: Peregrine Pharmaceuticals Clinical Pipeline

Figure 12-10: Seattle Genetics Clinical Pipeline

## *List of Tables*

Following Information For Each Drug Profile in Covered in More than 500 Tables in Report:

- Drug Profile Overview
- Active Indication
- Orphan Designation
- Brand Name
- Phase of Development

- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class